Next Article in Journal
Firing up the Tumor Microenvironment with Nanoparticle-Based Therapies
Next Article in Special Issue
Bacteria from Infectious Particles to Cell Based Anticancer Targeted Drug Delivery Systems
Previous Article in Journal
Wharton’s Jelly Mesenchymal Stromal Cells and Derived Extracellular Vesicles as Post-Myocardial Infarction Therapeutic Toolkit: An Experienced View
Previous Article in Special Issue
The Cysteine-Containing Cell-Penetrating Peptide AP Enables Efficient Macromolecule Delivery to T Cells and Controls Autoimmune Encephalomyelitis
Review

Peptide Inhibitors of Vascular Endothelial Growth Factor A: Current Situation and Perspectives

1
Institute of Chemistry, St. Petersburg State University, Universitetsky pr. 26, Peterhof, 198504 St. Petersburg, Russia
2
Division of Pharmaceutical Biosciences, University of Helsinki, Viikinkaari 5 E, 00014 Helsinki, Finland
3
School of Pharmacy, University of Eastern Finland, Yliopistonranta 1 C, 70211 Kuopio, Finland
*
Authors to whom correspondence should be addressed.
Academic Editor: David Barlow
Pharmaceutics 2021, 13(9), 1337; https://doi.org/10.3390/pharmaceutics13091337
Received: 30 June 2021 / Revised: 18 August 2021 / Accepted: 24 August 2021 / Published: 26 August 2021
(This article belongs to the Special Issue Advances in Delivering Protein and Peptide Therapeutics)
Vascular endothelial growth factors (VEGFs) are the family of extracellular signaling proteins involved in the processes of angiogenesis. VEGFA overexpression and altered regulation of VEGFA signaling pathways lead to pathological angiogenesis, which contributes to the progression of various diseases, such as age-related macular degeneration and cancer. Monoclonal antibodies and decoy receptors have been extensively used in the anti-angiogenic therapies for the neutralization of VEGFA. However, multiple side effects, solubility and aggregation issues, and the involvement of compensatory VEGFA-independent pro-angiogenic mechanisms limit the use of the existing VEGFA inhibitors. Short chemically synthesized VEGFA binding peptides are a promising alternative to these full-length proteins. In this review, we summarize anti-VEGFA peptides identified so far and discuss the molecular basis of their inhibitory activity to highlight their pharmacological potential as anti-angiogenic drugs. View Full-Text
Keywords: VEGF; VEGFA; VEGFR; peptide; affinity; binding; angiogenesis VEGF; VEGFA; VEGFR; peptide; affinity; binding; angiogenesis
Show Figures

Figure 1

MDPI and ACS Style

Guryanov, I.; Tennikova, T.; Urtti, A. Peptide Inhibitors of Vascular Endothelial Growth Factor A: Current Situation and Perspectives. Pharmaceutics 2021, 13, 1337. https://doi.org/10.3390/pharmaceutics13091337

AMA Style

Guryanov I, Tennikova T, Urtti A. Peptide Inhibitors of Vascular Endothelial Growth Factor A: Current Situation and Perspectives. Pharmaceutics. 2021; 13(9):1337. https://doi.org/10.3390/pharmaceutics13091337

Chicago/Turabian Style

Guryanov, Ivan, Tatiana Tennikova, and Arto Urtti. 2021. "Peptide Inhibitors of Vascular Endothelial Growth Factor A: Current Situation and Perspectives" Pharmaceutics 13, no. 9: 1337. https://doi.org/10.3390/pharmaceutics13091337

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop